Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Teyi Pharmaceutical GroupLtd Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.3yrs

Son yönetim güncellemeleri

Recent updates

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Jun 06

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Apr 26

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Mar 06

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Feb 27

CEO

Teyi Pharmaceutical GroupLtd CEO'su yok ya da onlar hakkında elimizde veri yok.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Songqing Xu	Deputy General Manager & Vice Chairman of The Board	no data	CN¥574.70k	7.95% CN¥ 349.3m
Xiliang Chen	CFO, Deputy GM	2.3yrs	CN¥557.40k	Veri yok
Mingjian Zhang	Chairman of the Supervisory Board	no data	Veri yok	Veri yok
Beijing Lu	Non-Independent Director	2.3yrs	CN¥87.00k	Veri yok
Danqing Xu	Chairman & GM	no data	CN¥611.50k	27.44% CN¥ 1.2b
Guisheng Li	Independent Director	2.3yrs	CN¥87.00k	Veri yok
Jiajun Shen	Shareholder Supervisor	2.3yrs	Veri yok	Veri yok
Yanming Cao	Independent Director	2.3yrs	CN¥87.00k	Veri yok

2.3yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 002728 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Teyi Pharmaceutical GroupLtd Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

High number of new and inexperienced directors

High number of new directors

Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments

Recent updates

Investor sentiment improves as stock rises 22%

Teyi Pharmaceutical Group Co.,Ltd to Report Q3, 2024 Results on Oct 26, 2024

Now 24% overvalued

Now 20% overvalued

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2024 Results on Jul 19, 2024

Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) announces an Equity Buyback for CNY 120 million worth of its shares.

We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Can Stay On Top Of Its Debt

Why Teyi Pharmaceutical GroupLtd's (SZSE:002728) Shaky Earnings Are Just The Beginning Of Its Problems

Investor sentiment deteriorates as stock falls 15%

First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.33 in 1Q 2023)

Teyi Pharmaceutical Group Co.,Ltd to Report Q1, 2024 Results on Apr 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 22% overvalued

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd, Annual General Meeting, Mar 28, 2024

Teyi Pharmaceutical Group Co.,Ltd's (SZSE:002728) Shares Bounce 29% But Its Business Still Trails The Market

Here's Why We Think Teyi Pharmaceutical GroupLtd (SZSE:002728) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 18%

High number of new and inexperienced directors

Teyi Pharmaceutical Group Co.,Ltd to Report Fiscal Year 2023 Results on Mar 08, 2024

Investor sentiment improves as stock rises 21%

Third quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.11 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.051 in 2Q 2022)

Teyi Pharmaceutical Group Co.,Ltd Announces Final Dividend on A Shares for the Year 2022, Payable on May 26, 2023

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for 2022

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥0.62 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 24%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.071 (vs CN¥0.17 in 2Q 2021)

High number of new directors

Teyi Pharmaceutical Group Co.,Ltd Announces Management Appointments

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 10, 2022

First quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Teyi Pharmaceutical Group Co.,Ltd Approves Cash Dividend (Tax Included) for the Year 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.007 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.021 in 2Q 2020)

Investor sentiment improved over the past week

Teyi Pharmaceutical Group Co.,Ltd Proposes 2020 Final Profit Distribution Plan, Payable on 03 June 2021

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.22 (vs CN¥0.85 in FY 2019)

New 90-day low: CN¥10.51

New 90-day low: CN¥12.39

Teyi Pharmaceutical Group Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

Yueke Zhijing cancelled the acquisition of 5% stake in Teyi Pharmaceutical Group Co.,Ltd (SZSE:002728) from Xu Weigao, Xu Hengqing and Xu Lifang.

New 90-day low - CN¥13.52

Earnings released

Teyi Pharmaceutical Group Co.,Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş